Related Experiment Videos
Debrisoquine oxidation polymorphism in a Tasmanian population
1School of Pharmacy, University of Tasmania, Hobart, Australia.
European Journal of Clinical Pharmacology
|January 1, 1991
Summary
This study investigated debrisoquine hydroxylation in 152 healthy Tasmanians, finding a bimodal distribution of metabolic ratios. The results confirm the stability of debrisoquine polymorphism in Caucasian populations.
Area of Science:
- Pharmacogenetics
- Drug Metabolism
- Human Genetics
Background:
- Debrisoquine (D) is a drug metabolized by cytochrome P450 enzymes.
- Genetic variations influence drug metabolism, leading to different phenotypes.
- Understanding debrisoquine polymorphism is crucial for personalized medicine.
Purpose of the Study:
- To determine the debrisoquine hydroxylation phenotype in a healthy Caucasian population in Tasmania.
- To assess the prevalence of poor metabolizers (PMs) and extensive metabolizers (EMs) of debrisoquine.
- To investigate if the debrisoquine phenotype is associated with sex.
Main Methods:
- 152 unselected healthy Tasmanian subjects were administered a 10 mg oral dose of debrisoquine.
- Urine was collected for 8 hours post-dose.
- The ratio of debrisoquine to 4-hydroxydebrisoquine (metabolic ratio, MR) was determined.
Main Results:
- Metabolic ratio (MR) values showed a bimodal distribution.
- 8.6% of subjects (13 individuals) were identified as poor metabolizers (MR 13.8-93.3).
- The remaining subjects were extensive metabolizers (MR 0.04-5.4), with no association found between phenotype and sex.
Conclusions:
- The debrisoquine hydroxylation phenotype exhibits a stable polymorphism in a Caucasian population, even after migration.
- This study confirms the genetic constancy of debrisoquine metabolism in this group.
- The findings support the importance of pharmacogenetic profiling for predicting drug response.